Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026)
Alvotech's (ALVO) quarterly Net Income towards Common Stockholders came in at -$66.7 million in Q2 2026, down 397.12% on a YoY basis from $22.5 million in Q2 2025, and down 7181.0% quarter-over-quarter from $942000.0 in Q1 2026.
Analysis
Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$66.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 397.12% year-over-year to -$66.7 million; the trailing twelve-month figure through Jun 2026 stood at -$278.7 million (down 56.91% YoY), and the FY2025 full-year result was $244.8 million, up 220.42% from the prior year.
- Net Income towards Common Stockholders slipped to -$66.7 million in Q2 2026 per ALVO's latest filing, from $942000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $405.2 million in Q2 2022 and bottomed at -$750.4 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$169.1 million across 5 years, with a median of -$126.6 million in 2023.
- The widest YoY moves for Net Income towards Common Stockholders: up 133.32% in 2025, down 626.08% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$568.7 million in 2022, then slipped by 20.15% to -$683.3 million in 2023, then surged by 70.25% to -$203.3 million in 2024, then surged by 131.36% to $63.7 million in 2025, then plunged by 204.64% to -$66.7 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$66.7 million, $942000.0, and $63.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | -118.80 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.73 Bn | 396.53 Mn | 46.85 Mn |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | 69.61 Mn |
| 5 | Bausch Health Companies | 2.31 Bn | 475.75 Mn | 2.10 Bn | 260.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -66.70 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 24.70 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 711.29 Mn | 93.47 Mn | 30.35 Mn |
| 9 | Fennec Pharmaceuticals | 396.40 Mn | 355.15 Mn | 17.15 Mn | 1.97 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.70 Mn |
| Mar 31, 2026 | 942,000.00 |
| Dec 31, 2025 | 63.74 Mn |
| Sep 30, 2025 | -276.69 Mn |
| Jun 30, 2025 | -13.42 Mn |
| Mar 31, 2025 | 77.16 Mn |
| Dec 31, 2024 | -203.26 Mn |
| Sep 30, 2024 | -38.11 Mn |
| Jun 30, 2024 | 88.37 Mn |
| Mar 31, 2024 | -231.61 Mn |
| Dec 31, 2023 | -683.29 Mn |
| Aug 31, 2023 | -186.56 Mn |
| Jun 30, 2023 | 148.38 Mn |
| Mar 20, 2023 | -750.37 Mn |
| Dec 31, 2022 | -568.72 Mn |
| Aug 31, 2022 | -218.62 Mn |
| Jun 30, 2022 | 405.24 Mn |
| Mar 20, 2022 | -589.71 Mn |
| Dec 31, 2021 | -148.94 Mn |
| Sep 30, 2021 | -125.39 Mn |